GHO Capital buys Velocity Clinical Research for about $500m

Covid has accelerated Velocity's growth plan by one to two years, while illustrating the clinical site organization's ability to efficiently ramp up operations, adapting to the needs of CROs and patients.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this